Ignite Creation Date:
2024-05-06 @ 7:44 PM
Last Modification Date:
2024-10-26 @ 3:12 PM
Study NCT ID:
NCT06111417
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-02-12
First Post:
2023-10-20
Brief Title:
Use of an Ultra-rapid BRCA12 Status Screening Test in Theranostic Indication Performance and Interest for Patients and Practitioners
Sponsor:
Centre Georges Francois Leclerc
Organization:
Centre Georges Francois Leclerc
Study Overview
Official Title:
Use of an Ultra-rapid BRCA12 Status Screening Test in Theranostic Indication Performance and Interest for Patients and Practitioners
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TURBO
Brief Summary:
The time taken to obtain the results of germline mutations in BRCA1 and BRCA2 has become a major issue in adapting the therapeutic management of patients particularly those with breast cancer
The time taken to obtain the results of BRCA12 tests in routine laboratories with a view to personalised treatment can range from a few weeks to a few months The waiting time required to obtain results is likely to cause stress and anxiety in cancer patients The investigators hypothesise that ultra-rapid testing can reduce anxiety about patients genetic status and improve their mental well-being
The main objective of this project is to compare the results obtained with an ultra-fast kit developed by ONT with those obtained with the current gold standard NGS sequencing
The time taken to obtain the results of BRCA12 tests in routine laboratories with a view to personalised treatment can range from a few weeks to a few months The waiting time required to obtain results is likely to cause stress and anxiety in cancer patients The investigators hypothesise that ultra-rapid testing can reduce anxiety about patients genetic status and improve their mental well-being
The main objective of this project is to compare the results obtained with an ultra-fast kit developed by ONT with those obtained with the current gold standard NGS sequencing
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None